Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Human Immunodeficiency Virus | Research

Need for informed providers: exploring LA-PrEP access in focus groups with PrEP-indicated communities in Baltimore, Maryland

Authors: Rose Pollard Kaptchuk, Amber M. Thomas, Amit “Mickey” Dhir, Sunil S. Solomon, Steven J. Clipman

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

The approval of long-acting pre-exposure prophylaxis PrEP (LA-PrEP) in the United States brings opportunities to overcome barriers of oral PrEP, particularly among sexual and gender minority communities who bear a higher HIV burden. Little is known about real-time decision-making among potential PrEP users of LA-PrEP post-licensure.

Methods

We held focus group discussions with people assigned male at birth who have sex with men in Baltimore, Maryland to explore decision-making, values, and priorities surrounding PrEP usage. A sexual and gender minority-affirming health center that provides PrEP services supported recruitment. Discussions included a pile-sorting activity and were audio-recorded. Recordings were transcribed and analyzed iteratively, combining an inductive and deductive approach.

Results

We held five focus groups from Jan-June 2023 with 23 participants (21 cisgender men who have sex with men, two transgender women who have sex with men; mean age 37). Among participants, 21 were on oral PrEP, one was on injectable PrEP, and one had never taken PrEP. Most had never heard about LA-PrEP. When making decisions about PrEP, participants particularly valued efficacy in preventing HIV, side effects, feeling a sense of security, and ease of use. Perceptions varied between whether oral or injectable PrEP was more convenient, but participants valued the new opportunity for a choice in modality. Factors influencing PrEP access included cost, individual awareness, provider awareness, and level of comfort in a healthcare environment. Participants emphasized how few providers are informed about PrEP, placing the burden of being informed about PrEP on them. Comfort and trust in a provider superseded proximity as considerations for if and where to access PrEP.

Conclusions

There is still low awareness about LA-PrEP among sexual and gender minority communities; thus, healthcare providers have a critical role in influencing access to LA-PrEP. Despite this, providers are still vastly underinformed about PrEP and underprepared to support clients in contextualized ways. Clients are more likely to engage in care with affirming providers who offer non-judgmental conversations about sex and life experiences. Provider education in the United States is urgently needed to better support clients in choosing a PrEP modality that is right for them and supporting adherence for effective HIV prevention.
Literature
1.
Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States 2017–2021. 2023.
2.
3.
Klein PW, Psihopaidas D, Xavier J, Cohen SM. HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration’s Ryan White HIV/AIDS program: a retrospective study. PLoS Med. 2020;17(5):e1003125.PubMedPubMedCentralCrossRef
4.
5.
6.
Murchu EO, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ open. 2022;12(5):e048478.CrossRef
7.
8.
Centers for Disease Control and Prevention. Core indicators for monitoring the ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2023; and preexposure prophylaxis (PrEP) data reported through March 2023. HIV Surveillance Data Table 2023;4(3)2023.
9.
Wu L, Schumacher C, Chandran A, Fields E, Price A, Greenbaum A, et al. Patterns of PrEP retention among HIV pre-exposure prophylaxis users in Baltimore City, Maryland. JAIDS J Acquir Immune Defic Syndr. 2020;85(5):593–600.PubMedCrossRef
10.
11.
Schumacher CM, Tao X, Chandran A, Fields E, Price A, Greenbaum A, et al. Reaching those most at risk for HIV Acquisition: evaluating Racial/Ethnic disparities in the Preexposure Prophylaxis Care Continuum in Baltimore City, Maryland. JAIDS J Acquir Immune Defic Syndr. 2021;87(5):1145–53.PubMedCrossRef
12.
FDA Approves First. Injectable Treatment for HIV Pre-exposure Prevention [press release]. December 20, 2021.
13.
Mitchell KM, Boily M-C, Hanscom B, Moore M, Todd J, Paz-Bailey G et al. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. The Lancet Regional Health–Americas. 2023;18.
14.
Balasubramanian R, Kasaie P, Schnure M, Dowdy DW, Shah M, Fojo AT. Projected impact of expanded long-acting injectable PrEP use among men who have sex with men on local HIV epidemics. JAIDS J Acquir Immune Defic Syndr. 2022;91(2):144–50.PubMedCrossRef
15.
Lorenzetti L, Dinh N, van der Straten A, Fonner V, Ridgeway K, Rodolph M, et al. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition. J Int AIDS Soc. 2023;26(S2):e26107.PubMedPubMedCentralCrossRef
16.
Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, et al. Expanding the Menu of HIV Prevention options: a qualitative study of experiences with Long-Acting Injectable Cabotegravir as PrEP in the context of a phase II trial in the United States. AIDS Behav. 2018;22(11):3540–9.PubMedPubMedCentralCrossRef
17.
Schoenberg P, Edwards OW, Merrill L, Martinez CA, Stephenson R, Sullivan PS, et al. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study. J Int AIDS Soc. 2023;26(3):e26077.PubMedPubMedCentralCrossRef
18.
Biello KB, Hosek S, Drucker MT, Belzer M, Mimiaga MJ, Marrow E, et al. Preferences for Injectable PrEP among Young U.S. Cisgender men and Transgender women and men who have sex with men. Arch Sex Behav. 2018;47(7):2101–7.PubMedCrossRef
19.
Patel RR, Crane JS, López J, Chan PA, Liu AY, Tooba R, et al. Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. PLoS ONE. 2018;13(12):e0209484.PubMedPubMedCentralCrossRef
20.
Parsons JT, Rendina HJ, Whitfield THF, Grov C. Familiarity with and preferences for oral and long-acting Injectable HIV pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual men in the U.S. AIDS Behav. 2016;20(7):1390–9.PubMedPubMedCentralCrossRef
21.
The Lancet HIV. Equitable access to long-acting PrEP on the way? Lancet HIV. 2022;9(7):e449.CrossRef
22.
Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure Prophylaxis in the United States: a narrative review. Adv Ther. 2020;37(5):1778–811.PubMedPubMedCentralCrossRef
23.
24.
Liegeon G, Ghosn J. Long-acting injectable cabotegravir for PrEP: a game-changer in HIV prevention? HIV Med. 2023;24(6):653–63.PubMedCrossRef
25.
Zapata JP, Zamantakis A, Queiroz AAFLN. Identification of determinants and implementation strategies to increase long-acting Injectable PrEP for HIV Prevention among latino men who have sex with men (MSM). J Racial Ethnic Health Disparities. 2023:1–10.
26.
Pike C, Bekker L-G. Interrogating the promise of long-acting HIV pre-exposure prophylaxis. Trends Mol Med. 2023;29(2):93–8.PubMedCrossRef
27.
Keddem S, Thatipelli S, Caceres O, Roder N, Momplaisir F, Cronholm P. Barriers and facilitators to long-acting Injectable HIV Pre-exposure Prophylaxis implementation in primary care since its approval in the United States. JAIDS J Acquir Immune Defic Syndr. 2024;95(4):370–6.PubMedCrossRef
28.
29.
Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. Medical care. 1981:127– 40.
30.
Saurman E. Improving access: modifying Penchansky and Thomas’s theory of access. J Health Serv Res Policy. 2016;21(1):36–9.PubMedCrossRef
31.
Morgan DL. Planning and research design for focus groups. Focus Groups as Qualitative Res. 1997;16(104135):9781412984287.
32.
Kitzinger J. The methodology of focus groups: the importance of interaction between research participants. Sociol Health Illn. 1994;16(1):103–21.CrossRef
33.
34.
Morse JM, Field PA. Qualitative research methods for health professionals1995.
35.
Yeh H-W, Gajewski BJ, Perdue DG, Cully A, Cully L, Greiner KA, et al. Sorting it out: pile sorting as a mixed methodology for exploring barriers to cancer screening. Qual Quant. 2014;48(5):2569–87.PubMedCrossRef
36.
Miles MB, Huberman AM, Saldaña J. Qualitative data analysis: a methods sourcebook. 3 ed. ed. Los Angeles: Sage Los Angeles; 2014.
37.
Psaros C, Hill-Rorie J, Quint M, Horvitz C, Dormitzer J, Biello KB et al. A qualitative exploration of how to support PrEP adherence among young men who have sex with men. AIDS Care. 2023:1–12.
38.
Arnold T, Giorlando KK, Barnett AP, Gaudiano BA, Rogers BG, Whiteley L et al. Social, structural, behavioral, and clinical barriers influencing pre-exposure Prophylaxis (PrEP) use among Young Black men who have sex with men in the South: a qualitative update to a 2016 study. Arch Sex Behav. 2023.
39.
Dubov A, Galbo P, Altice FL, Fraenkel L. Stigma and shame experiences by MSM who take PrEP for HIV Prevention: a qualitative study. Am J Men’s Health. 2018;12(6):1843–54.CrossRef
40.
Pinto RM, Berringer KR, Melendez R, Mmeje O. Improving PrEP implementation through Multilevel interventions: a synthesis of the literature. AIDS Behav. 2018;22(11):3681–91.PubMedPubMedCentralCrossRef
41.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentralCrossRef
42.
Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.PubMedPubMedCentralCrossRef
43.
Philbin MM, Parker CM, Parker RG, Wilson PA, Garcia J, Hirsch JS. The Promise of Pre-exposure Prophylaxis for Black men who have sex with men: an Ecological Approach to attitudes, beliefs, and barriers. AIDS Patient Care STDS. 2016;30(6):282–90.PubMedPubMedCentralCrossRef
44.
Dean LT, Predmore Z, Skinner A, Napoleon S, Chan PA, Raifman J. Optimizing uptake of Long-Acting Injectable pre-exposure Prophylaxis for HIV Prevention for men who have sex with men. AIDS Behav. 2023;27(8):2606–16.PubMedPubMedCentralCrossRef
45.
Yang C, Krishnan N, Kelley E, Dawkins J, Akolo O, Redd R, et al. Beyond HIV prevention: a qualitative study of patient-reported outcomes of PrEP among MSM patients in two public STD clinics in Baltimore. AIDS Care. 2020;32(2):238–41.PubMedCrossRef
46.
John SA, Zapata JP, Dang M, Pleuhs B, O’Neil A, Hirshfield S, et al. Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old. Sci Rep. 2023;13(1):5116.PubMedPubMedCentralCrossRef
47.
Pleuhs B, Quinn KG, Walsh JL, Petroll AE, John SA. Health Care Provider barriers to HIV Pre-exposure Prophylaxis in the United States: a systematic review. AIDS Patient Care STDS. 2020;34(3):111–23.PubMedPubMedCentralCrossRef
48.
Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26(6):684–93.PubMedCrossRef
49.
Wilson K, Bleasdale J, Przybyla SM. Provider-patient communication on Pre-exposure Prophylaxis (Prep) for HIV Prevention: An Exploration of Healthcare Provider challenges. Health Commun. 2021;36(13):1677–86.PubMedCrossRef
50.
Przybyla S, Fillo J, Kamper-DeMarco K, Bleasdale J, Parks K, Klasko-Foster L, et al. HIV pre-exposure prophylaxis (PrEP) knowledge, familiarity, and attitudes among United States healthcare professional students: a cross-sectional study. Prev Med Rep. 2021;22:101334.PubMedPubMedCentralCrossRef
51.
Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contraception. 2016;93(5):463–9.PubMedCrossRef
52.
Skolnik AA, Bokhour BG, Gifford AL, Wilson BM, Van Epps P. Roadblocks to PrEP: what Medical records Reveal about Access to HIV Pre-exposure Prophylaxis. J Gen Intern Med. 2020;35(3):832–8.PubMedCrossRef
53.
Sell J, Chen R, Huber C, Parascando J, Nunez J. Primary care provider HIV PrEP knowledge, attitudes, and prescribing habits: a cross-sectional survey of late adopters in rural and suburban practice. J Prim Care Community Health. 2023;14:21501319221147254.PubMedPubMedCentralCrossRef
54.
Valente PK, Rusley JC, Operario D, Biello KB. Readiness to provide oral and injectable PrEP for sexual and Gender Minority Youth among Healthcare Providers and clinics in the U.S. Northeast. J Adolesc Health. 2023;72(5):722–9.PubMedPubMedCentralCrossRef
55.
Rao S, Reed AE, Parchem B, Edelman EJ, Magnus M, Hansen NB, et al. Optimizing Provider Preexposure Prophylaxis (PrEP) training: a cross-sectional analysis of recommendations from providers across the PrEP implementation Cascade. AIDS Behav. 2022;26(1):218–31.PubMedCrossRef
56.
Turner L, Roepke A, Wardell E, Teitelman AM. Do you PrEP? A review of primary care provider knowledge of PrEP and attitudes on prescribing PrEP. J Assoc Nurses AIDS Care. 2018;29(1):83–92.PubMedCrossRef
57.
Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, et al. Knowledge is Power! Increased provider knowledge scores regarding pre-exposure Prophylaxis (PrEP) are Associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10.PubMedPubMedCentralCrossRef
58.
Henny KD, Duke CC, Geter A, Gaul Z, Frazier C, Peterson J, et al. HIV-Related training and correlates of knowledge, HIV Screening and Prescribing of nPEP and PrEP among Primary Care providers in Southeast United States, 2017. AIDS Behav. 2019;23(11):2926–35.PubMedPubMedCentralCrossRef
59.
Laborde ND, Kinley PM, Spinelli M, Vittinghoff E, Whitacre R, Scott HM, et al. Understanding PrEP persistence: provider and patient perspectives. AIDS Behav. 2020;24(9):2509–19.PubMedPubMedCentralCrossRef
60.
Devarajan S, Sales JM, Hunt M, Comeau DL. PrEP and sexual well-being: a qualitative study on PrEP, sexuality of MSM, and patient-provider relationships. AIDS Care. 2020;32(3):386–93.PubMedCrossRef
61.
Sewell WC, Powell VE, Ball-Burack M, Mayer KH, Ochoa A, Marcus JL, et al. Brief report: I didn’t really have a primary care provider until I got PrEP: patients’ perspectives on HIV Preexposure Prophylaxis as a gateway to Health Care. J Acquir Immune Defic Syndr. 2021;88(1):31–5.PubMedPubMedCentralCrossRef
62.
Raifman JR, Flynn C, German D. Healthcare provider contact and pre-exposure prophylaxis in Baltimore men who have sex with men. Am J Prev Med. 2017;52(1):55–63.PubMedCrossRef
63.
Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29(11):1351–8.PubMedPubMedCentralCrossRef
64.
Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV Pre-exposure Prophylaxis (PrEP): assumptions about sexual risk compensation and implications for Access. AIDS Behav. 2014;18(2):226–40.PubMedPubMedCentralCrossRef
65.
Fisher CB, Fried AL, Desmond M, Macapagal K, Mustanski B. Facilitators and barriers to participation in PrEP HIV Prevention trials involving Transgender Male and female adolescents and emerging adults. AIDS Educ Prev. 2017;29(3):205–17.PubMedPubMedCentralCrossRef
66.
Aisner AJ, Zappas M, Marks A. Primary care for Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning (LGBTQ) patients. J Nurse Practitioners. 2020;16(4):281–5.CrossRef
67.
Sevelius JM, Keatley J, Calma N, Arnold E. I am not a man’: Trans-specific barriers and facilitators to PrEP acceptability among transgender women. Rethinking MSM, Trans* and other categories in HIV Prevention. Routledge; 2018. pp. 242–57.
68.
Jaramillo J, Pagkas-Bather J, Waters K, Shackelford LB, Campbell RD, Henry J, et al. Perceptions of sexual risk, PrEP services, and peer Navigation Support among HIV-Negative latinx and black men who have sex with men (MSM) Residing in Western Washington. Sexuality Res Social Policy. 2022;19(3):1058–68.CrossRef
69.
Tao J, Sosnowy C, Arnold T, Kapadia J, Parent H, Rogers BG, et al. Perspectives of a peer-driven approach to improve pre-exposure prophylaxis and HIV prevention among Black/African American and Hispanic/Latino men who have sex with men. Sex Health. 2023;20(5):453–60.PubMedPubMedCentralCrossRef
70.
Edeza A, Karina Santamaria E, Valente PK, Gomez A, Ogunbajo A, Biello K. Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies. AIDS Care. 2021;33(6):697–705.PubMedCrossRef
71.
Hull SJ, Tessema H, Thuku J, Scott RK. Providers PrEP: identifying Primary Health care providers’ biases as barriers to Provision of Equitable PrEP Services. J Acquir Immune Defic Syndr. 2021;88(2):165–72.PubMedCrossRef
72.
Grimsrud A, Wilkinson L, Delany-Moretlwe S, Ehrenkranz P, Green K, Murenga M, et al. The importance of the how: the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment. J Int AIDS Soc. 2023;26(S2):e26095.PubMedPubMedCentralCrossRef
Metadata
Title
Need for informed providers: exploring LA-PrEP access in focus groups with PrEP-indicated communities in Baltimore, Maryland
Authors
Rose Pollard Kaptchuk
Amber M. Thomas
Amit “Mickey” Dhir
Sunil S. Solomon
Steven J. Clipman
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18595-7

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue

Research

Evaluation of physical fitness and health of young children aged between 3 and 6 based on cluster and factor analyses

Research

Self-efficacy, mindfulness, and perceived social support as resources to maintain the mental health of students in Switzerland’s universities of applied sciences: a cross-sectional study

Research

The Role of Chief Medical officers in making Public Health Overview Documents in Norwegian Municipalities. A qualitative Study

Research

Co-design and evaluation of a digital serious game to promote public awareness about pancreatic cancer

Research

Adulterants present in the San Diego county fentanyl supply: a laboratory analysis of seized law enforcement samples

Research

Financial inclusion and improved water usage among households in Ghana